Viral Hemorrhagic Fever Clinical Trials

Find Viral Hemorrhagic Fever Clinical Trials Near You

UMIT-2: A Randomized, Multi-country, Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for Crimean-Congo Haemorrhagic Fever

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

CCHF has a wide geographical distribution with cases mainly occurring in Asia, the Middle East, South-Eastern Europe and Africa. Since its emergence in 2002, Turkiye has been the epicentre of activity worldwide reporting up to more than 1000 cases annually. CCHF case management relies on the provision of optimised supportive care; therapeutic options lack a robust evidence base The UMIT-2 Trial (UMIT = 'Hope' in Turkish) will be the first large randomised controlled trial of novel therapeutics in CCHF, undertaken in multiple trial sites in Turkiye and Iraq. It uses an efficient adaptive platform design (Phase IIb), focussed on antiviral efficacy with interim monitoring to introduce new arms and allow early stopping for futility, efficacy, or safety

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adult in-patients (≥18 years) at the time of screening.

• Confirmed CCHF infection: Laboratory confirmed CCHF infection defined as positive polymerase chain reaction (PCR) test within 5 days prior to randomisation.

• Ability to provide informed consent signed by study patient or legally acceptable representative (for illiterate individuals).

• Women of childbearing potential (WOCBP) and male patients who are sexually active with WOCBP must agree to use a highly effective method of contraception (as outlined in Protocol section 5.4) from the first administration of trial treatment, throughout trial treatment and for the duration outlined.

• Severity Grading System (SGS) for CCHF - Low/moderate risk. (Appendix 15).

• Less than or equal to 7 days from onset of CCHF symptoms.

• Willingness to participate in the full protocol.

• Requirement to be hospitalised for treatment.

Locations
Other Locations
Turkey
Atatürk University
RECRUITING
Erzurum
Ondokuz Mayıs University
RECRUITING
Samsun
Sivas Cumhuriyet University
RECRUITING
Sivas
Contact Information
Primary
Alex Hainsworth
UMIT@lstmed.ac.uk
0151 702 9460
Time Frame
Start Date: 2026-06-04
Estimated Completion Date: 2028-08-31
Participants
Target number of participants: 378
Treatments
Active_comparator: Optimised standard of care (oSOC)
Optimised standard of care will include treatment per national guidelines for CCHF case management in Turkiye and Iraq, and any other supportive medication or therapies as required. The standard of care arm will exclude any medicine defined as investigation arms of this study. Any supportive medication or therapies will be recorded on the patient CRFs.
Active_comparator: Arm B: Favipiravir
Day 1 (First 24 hours): IV Favipiravir 2600 mg twice daily (BD) Day 2 (24-48 hours): IV Favipiravir 1200 mg twice daily (BD) Day 3 -7 (Post 48 hours): Oral (PO) Favipiravir 1200 mg twice daily (BD)1 until hospital discharge up to 7 days (14 doses) whichever is soonest.~Plus any additional supportive care deemed necessary by the study investigator
Active_comparator: Arm C: Ribavirin
Day 1 (First 24 hours): IV Ribavirin (33mg/kg) loading dose followed by IV Ribavirin 16mg/kg every 6 hours Day 2 (24-48 hours): IV Ribavirin 16mg/kg four times daily (QDS) Days 3-5: Oral (PO) Ribavirin 16mg/kg four times daily (QDS) Days 6 -7: Oral (PO) Ribavirin 8mg/kg four times daily (QDS) until hospital discharge~Plus any additional supportive care deemed necessary by the study investigator
Related Therapeutic Areas
Sponsors
Collaborators: Medical Research Council, MEDEX
Leads: Liverpool School of Tropical Medicine

This content was sourced from clinicaltrials.gov